Skip to main content
Premium Trial:

Request an Annual Quote

New England Biolabs, TTP Partner to Provide MDx Development Services

NEW YORK (GenomeWeb) – New England Biolabs and TTP have established a non-exclusive partnership to offer services to molecular diagnostic technology developers.

Together, Ipswich, Massachusetts-based NEB and Cambridge, UK-based TTP will offer product-development services spanning instrumentation, consumables, and reagents.

More specifically, the partnership is focused on supporting customers in the MDx and wider life science space to "rapidly transition ideas into commercially successful products," the partners said.

The services will couple NEB's catalog of reagents and expertise in enzyme development and manufacturing with TTP's Desktop Biology product development and physical engineering know-how.

"At TTP, we understand the fundamental steps required to convert lab-based biological processes to a functional low-cost disposable and instrument, and together we are now able to fast track more complete product development solutions," Giles Sanders, consultant at TTP, said in a statement.

"NEB was already committed to developing novel enzyme specificities for incorporation into new clinical and molecular testing platforms," Breton Hornblower, product manager at NEB, said in a statement. "Our customers will now be able to access these reagents as part of these services, along with those of TTP."

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.